Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Schering-Plough receives Simponi authorisation

Schering-Plough receives Simponi authorisation

14th April 2009

Schering-Plough has received its first approval for Simponi.

It is the only biologic therapy that has been approved for three distinct rheumatologic diseases – psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis

The once-monthly therapy, when used in combination with methotrexate, is designed to reduce the signs and symptoms of the conditions.

Developed and discovered by Centocor Ortho Biotech, Simponi will be exclusively marketed by Schering-Plough everywhere outside the US ? apart from Japan, Indonesia and Taiwan.

Executive vice-president of the Schering-Plough Dr Thomas P Koestler said the drug will offer patients an important and convenient treatment option.

“Simponi expands our leading immunology franchise in meeting the needs of the rheumatology community,” he commented.

Last month, Schering-Plough was named as an Energy Star Partner of the Year by the Environmental Protection Agency.

It was awarded the honour for its work to reduce the number of greenhouse gas emissions.

Director of energy at the company Tom Pagliuco explained managing energy was “critical” to the business’ operations.

He added that it uses alternative sources, including solar panels and a tri-generation system.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.